HTG Molecular Diagnostics, Inc. (“HTG”) is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power ofHTG EdgeSeq chemistry and automation with next-generationsequencing(NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services.
|Bank Name||HTG Molecular Diagnostics, Inc.|
|Industry||Biotechnology: Laboratory Analytical Instruments|
|CEO||Mr. Timothy B. Johnson|